Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice: The Get with the Guidelines-Heart Failure (GWTG-HF) Registry
Muthiah Vaduganathan, Stephen J. Greene, Shuaiqi Zhang, Maria Grau-Sepulveda, Adam D. Devore, Javed Butler, Paul A. Heidenreich, Joanna C. Huang, Michelle M. Kittleson, Karen E. Joynt Maddox, James J. McDermott, Anjali Tiku Owens, Pamela N. Peterson, Scott D. Solomon, Orly Vardeny, Clyde W. Yancy, Gregg C. Fonarow
Dive into the research topics of 'Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice: The Get with the Guidelines-Heart Failure (GWTG-HF) Registry'. Together they form a unique fingerprint.